AHR Stock Forecast & Price Target

American Healthcare REIT is supported by a compelling blend of above-average internal growth and accretive external expansion, with its Trilogy-linked integrated senior health campuses and traditional SHOP platforms benefiting from strong occupancy, pricing, and favorable supply-demand dynamics. Management has already completed $1.4 billion to $2.1 billion of investments YTD in the cited periods, with additional awarded or pipeline deals that should lift same-store NOI, while estimates call for FFO or nFFO growth to remain elevated and core earnings growth to reach double digits across 2026-2028. The balance sheet also underpins the bullish view, as net debt-to-EBITDA is described between 2.5x and 1.2x and expected to drift lower with equity-funded acquisitions, preserving flexibility to pursue further growth without overextending leverage.

American Healthcare REIT is viewed negatively because its earnings quality and growth outlook are highly exposed to Trilogy, which generates over half of NOI and roughly half of Trilogy NOI comes from skilled nursing beds, making the REIT vulnerable to headline risk and operating volatility. A tougher SNF backdrop from potential Medicaid cuts or the repeal of Indiana’s IGT add-on rates could الضغط Medicaid reimbursement, slow the investment pace, and trim the 7-YR AFFO CAGR by 500 bps to 10%+, even as the long-term AFFO multiple is assumed to hold at 18.0x. With risks also tied to labor availability, seniors’ unwillingness to move, and the cost and availability of capital, the company faces a fragile regulatory and operating environment despite expected ~$2.5 billion of investments in 2026, including ~$2.1 billion completed YTD.